Beyond Brexit: The Future of British Pharma
Information
The United Kingdom left the European Union on December 31st, 2020. Before this, the EMA had already relocated its European HQ from London to Amsterdam, and there was considerable uncertainty on how the European Pharma Market would be impacted. This session will provide an analysis of the challenges presented by Brexit, and the impact on British Pharma.
- What is the impact of the UK leaving the EU on Pharma to date?
- What has changed?
- Security of supply for medical and pharmaceutical products
- Recent policy discussions on increasing the resilience of global supply chains
- How are manufacturers going to ensure continuity of supply in a post-Brexit world?
- How will innovation be impacted?
- What are the long-term implications of Brexit?
